B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GRIK1

MOLECULAR TARGET

glutamate ionotropic receptor kainate type subunit 1

UniProt: P39086NCBI Gene: 28979 compounds

GRIK1 (glutamate ionotropic receptor kainate type subunit 1) is targeted by 9 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GRIK1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1kainic acid3.8144
2nbqx3.5634
3s ampa3.0019
4rs ampa3.0019
5Glutamic Acid2.7715
6Glutamic Acid2.7715
7tezampanel anhydrous2.7114
82s4r 4 methylglutamate2.087
9alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid1.614

About GRIK1 as a Drug Target

GRIK1 (glutamate ionotropic receptor kainate type subunit 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 9 compounds with documented GRIK1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GRIK1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.